Clinical trial · Interventional
Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer
A Phase II Trial of Bryostatin 1 in Ovarian Cancer Administered by Weekly 24 Hour Intravenous Infusion
NCT00004008CI-TRIAL-00011105completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have ovarian epithelial cancer that has not responded to previous chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bryostatin 1 | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven ovarian epithelial cancer * Progressive disease during or after completion of at least one platinum based chemotherapy regimen * Bidimensionally measurable disease * At least 2 cm by x-ray, CT scan, or ultrasound * No active, symptomatic brain metastases (e.g., cerebral edema and/or progressive tumor growth) PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * WHO 0-2 Life expectancy: * At least 12 weeks Hematopoietic: * Hemoglobin at least 10 g/dL * WBC at least 4,000/mm3 * Platelet count at least 100,000/mm3 Hepatic: * Bilirubin no greater than 1.7 mg/dL * AST/ALT no greater than 2.5 times upper limit of normal (ULN) (no greater than 5 times ULN if liver metastases present) Renal: * Creatinine no greater than 1.4 mg/dL Other: * No active, uncontrolled infection * No nonmalignant systemic disease which would increase risk to patient * No other malignancies within the past 5 years except curatively treated basal or squamous cell skin cancer or carcinoma in situ of the cervix * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 2 months after study PRIOR CONCURRENT THERAPY: Biologic therapy: * At least 4 weeks since prior immunotherapy and recovered Chemotherapy: * See Disease Characteristics * At least 4 weeks since prior chemotherapy (6 weeks since nitrosoureas or mitomycin) and recovered * No more than 2 prior multidrug chemotherapy regimens * No more than 1 prior single agent chemotherapy regimen Endocrine therapy: * At least 4 weeks since prior endocrine therapy and recovered * No concurrent steroids * Concurrent hormone replacement therapy allowed Radiotherapy: * At least 4 weeks since prior radiotherapy (excluding palliative therapy) and recovered * No concurrent radiotherapy Surgery: * At least 4 weeks since prior major thoracic or abdominal surgery Other: * No other concurrent anticancer therapy or investigational drugs
References
Publications (0)
Data not yet available
No reference posted for this study.